@joryfleischauer

joryfleischauer has been a member of Linktree for 3 years and joined in May 2023. The social media accounts linked to from joryfleischauer are: • LinkedIn Besides social media accounts, joryfleischauer has populated their site with: • Selling the Script: The Introduction of Private Equity in Retail Pharmacy • Movement Disorder Side Effects Related to Adjunctive Use of an Atypical Antipsychotic in Patients With Major Depressive Disorder • Updates in CLL Treatment: 5-Year Off-Treatment Analyses From the CLL14 and MURANO Trials • Recognizing Negative Symptoms of Schizophrenia • First vs Second-Generation Antipsychotics: How Do They Work? • Mechanisms of Gastrointestinal Inflammation in Crohn’s Disease and Ulcerative Colitis • Changing Payer Management Dynamics at Play in Oncology • What Does Member Disruption Mean to Payers? • Predictors of Treatment-Emergent Affective Switch Video | NP Psych Navigator • Differentiating Unipolar and Bipolar Depression • Understanding Affective Switch in Bipolar I Disorder | NP Psych Navigator • TNF Inhibitors for Treating IBD: How They Work • Crohn’s Disease and Ulcerative Colitis: How Are They Different? • To Crush or Not to Crush: That is the Medication Administration Question • Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study • A Plain Language Summary on the Effect of the Medication Vibegron on Blood Pressure and Heart Rate in People With Overactive Bladder • Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials | Neurology and Therapy | Springer Nature Link • Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data • Complicated Overactive Bladder Management: Ingenta Connect • Poster & Abstract (ICS 2023) - Real-World Adherence and Persistence of Vibegron Versus Mirabegron and Anticholinergics in Patients With Overactive Bladder: A Retrospective Claims Analysis • Poster (RAV 2024) - Risk of Malignancy Excluding Nonmelanoma Skin Cancer in Patients With Moderate‑to‑Severe Atopic Dermatitis in the United States: A Population-Based Study Using Claims Data • Comparative analysis of real‐world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study • Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis - Advances in Therapy • Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments • Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder • CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis - Drugs - Real World Outcomes • Assessment of Codispensing Patterns of Mirabegron and Prespecified CYP2D6 Substrates in Patients with Overactive Bladder - Drugs - Real World Outcomes